

# Fact Sheet Investors

AUGUST 2007

## Value Drivers

- > Large, underserved target market
- > Experienced management team and unique technical and scientific expertise
- > Strong balance sheet
- > Accelerated path to commercialization
- > High value technology platform with multiple potential applications

## Our Mission

- > Discover, develop, manufacture and commercialize a complete pipeline of therapies, based on our unique technology platform
- > Address critical and unmet medical needs, in a cost-effective manner, for the benefit of health-care systems and the ultimate benefit of millions of patients

- > Maximize the commercial success of BioSyntech's products, through global partnerships and thereby offer long-term value to shareholders

## Company Profile

Established in 1995, BioSyntech, Inc. (TSX: BSY) has created and developed innovative biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery, to address critical and unmet medical needs of millions of patients.

The Company's technology platform is a family of hydrogels called BST-Gel®, liquid at low temperature and solid at human body temperature. To date BioSyntech has 40 patent applications pending and 70 patents granted.

BioSyntech employs 40 professionals and has a privileged relationship with Professor Michael Buschmann and his research team at the Ecole Polytechnique of the University of Montreal. His research laboratory is one of the largest and most advanced in the world in the field of cartilage regeneration.

## Lead Products: Developing Products for Large Potential Markets

Product	Therapeutic Area	Stage	Estimated Market Opportunity
BST-CarGel®	Cartilage repair	Canadian pivotal clinical trial	>\$1.4B
BST-DermOn™	Wound healing	Canadian pivotal clinical trial	>\$1.0B
BST-InPod™	Heel pain	In preparation for clinical trial	>\$1.5B

## Pipeline

Product	Therapeutic Area	Research	Preclinical	Pilot	Pivotal	Market
<b>Core Products</b>						
BST-CarGel®	Cartilage repair	[Progress bar: Research, Preclinical, Pilot, Pivotal]				
BST-DermOn™	Wound Healing	[Progress bar: Research, Preclinical, Pilot, Pivotal]				
BST-InPod™	Heel Pain	[Progress bar: Research, Preclinical, Pilot]				
<b>Early Stage Products</b>						
BST-Ossifil™	Bone Repair	[Progress bar: Research, Preclinical]				
BST-FTO	Gynecology	[Progress bar: Research, Preclinical]				
BST-Disc™	Disc Restoration	[Progress bar: Research]				

For contact information, visit our website  
[www.biosyntech.com](http://www.biosyntech.com)



# Fact Sheet Investors

AUGUST 2007

## Corporate Information

### Listing

TSX: BSY

### High/Low - 52 weeks

C\$0.25 - \$0.76

### Recent price

C\$0.50

### Outstanding Shares

95.4 million

### Market capitalization

C\$48 million

### Institutions

ProQuest Investments

Nicholas Piramal India Ltd. (NPIL)

Solidarity Fund QFL

Pappas Ventures

BDC

## Financial Highlights

### Year-end

March 31

### Cash and cash equivalents

C\$9.5 million (June 30, 2007)

### Cash burning rate

C\$800,000/month (June 30, 2007)

## Investor Relations Contacts

### Yvonne Kramer, Ph.D.

Senior Director, Corporate &  
Business Development  
(450) 686-2437, ext. 315

### The Equicom Group Inc.

Eric Bouchard  
(514) 844-7997  
ebouchard@equicomgroup.com

475 Armand-Frappier  
Laval (Quebec) H7V 4B3  
Tel: (450) 686-2437  
[www.biosyntech.com](http://www.biosyntech.com)

## Strategy: Focus on Bringing our Products to Market

Our strategy for the years ahead consists of:

- > Obtaining market approvals for our lead products in Canada, Europe and the US
- > Signing strategic licensing and distribution agreements for our lead products that will include upfront payments, milestone payments and royalties
- > Building a large-scale automated and FDA-compliant manufacturing unit
- > Developing our broad product pipeline

## Recent Highlights

- > Completed three transactions, raising \$28 million.
- > Signed marketing and distribution agreements with Korean and Indian companies.
- > Strengthened Board of Directors and Management Team.
- > Initiated enrolment for BST-CarGel pivotal trial.
- > Received regulatory approval to begin BST-DermOn pivotal trial.
- > Graduated to TSX from TSX-Venture exchange.

## Management Team

**Claude LeDuc** - President and Chief Executive Officer

**François Michaud, CA, CMA** - Chief Financial Officer

**Richard Lacombe, PhD, MBA** - Vice President, Clinical Affairs

**Eric DesRosiers, PhD, MBA** - Vice President, New Technologies and Operations

**Matthew Shive, PhD** - Vice President, Product Development

**Flor del Pilar Arana, BSc, MBA** - Vice President Regulatory Affairs & Quality

**Alberto Restrepo, MD** - Director, Medical Affairs

**Yvonne Kramer, PhD** - Senior Director, Corporate and Business Development

## Board of Directors

**Joseph Benarrosh - Chairman** - President, JJDS Capital Inc.

**Claude LeDuc** - President and Chief Executive Officer, BioSyntech

**Joyce Tsang, PhD** - General Partner, ProQuest Investments

**Rudy Huber** - Country Manager, 3I Implant Innovations

**Somesh Sharma, PhD** - Chief Scientific Officer, Nicholas Piramal India Ltd.

**Serge Savard** - Partner, Thibault, Messier, Savard

**Amine Selmani, PhD** - Director, Founder of BioSyntech

**Christophe Guy, PhD** - Director of Research and Innovation, Ecole Polytechnique de Montréal

